Document is current
Any future updates will be listed below
-
Authors
Taha, Muhamed-Kheir https://orcid.org/0000-0002-0716-3174
Weil-Olivier, Catherine https://orcid.org/0000-0001-5271-1945
Leng, Sean https://orcid.org/0000-0002-2690-8055
Dinleyici, Ener Cagri https://orcid.org/0000-0002-0339-0134
Yezli, Saber https://orcid.org/0000-0002-3380-7092
-
Funding
Funding for this research was provided by:
Sanofi Pasteur
- License Information
-
More Information
Article History
Received: 25 July 2025
Accepted: 2 December 2025
First Online: 21 December 2025
Declarations
:
: Muhamed-Kheir Taha conducts work contracts funded by GSK, Pfizer, and Sanofi for the Institut Pasteur, Paris. He also reports the patent NZ630133A “Vaccines for serogroup X meningococcus” issued with GSK. Catherine Weil-Olivier declares receiving fees, travel grants, and honoraria from Sanofi for attending scientific meetings and presentations on this topic. Sean Leng declares participation in Sanofi’s International Advisory Board on SARS-CoV-2 vaccine development and engaged in speaking for GSK on Shingrix vaccine. Ener Cagri Dinleyici declares performing contract work (advisory board member, speaker and grant) for Eskisehir Osmangazi University, funded by GSK, Pfizer, MSD, and Sanofi Pasteur. Saber Yezli declares receiving consultation fees, travel grants, and honoraria from Sanofi for attending scientific meetings and presentations.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
